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Background/Aims: The relationship between intestinal Be-
hçet’s disease (BD) and cancer remains unclear. We conduct-
ed a nationwide, population-based study to determine the 
risk of cancer in patients with intestinal BD. Methods: Using 
the National Health Insurance claims records, we collected 
data on 365 patients who had been diagnosed with intestinal 
BD between 2011 and 2014. Standardized incidence ratios 
(SIRs) of overall and site-specific cancers in patients with in-
testinal BD in comparison with the general population were 
calculated. Results: Among 167 men with intestinal BD, four 
cases of cancer were observed; among 191 women with BD, 
eight cases of cancer were observed. The risk of all cancers 
was significantly higher in women with intestinal BD than in 
women of the general population (SIR, 4.27; 95% confidence 
interval [CI], 1.84 to 8.41). However, in men with intestinal 
BD, the risk of all cancers was not significantly higher than 
that in men of the general population (SIR, 2.08; 95% CI, 0.57 
to 5.33). The risk of hematologic cancer was significantly 
higher in both men and women with intestinal BD than in 
their counterparts in the general population (SIR, 23.90; 
95% CI, 2.89 to 86.32 in men; SIR, 34.47; 95% CI, 4.17 to 
124.51 in women). In particular, patients with intestinal BD 
showed a higher risk of leukemia and myelodysplastic syn-
drome than the general population. Conclusions: Patients 
with intestinal BD demonstrated a higher risk of hematologic 
cancer, especially leukemia, than the general population. 
Furthermore, women with intestinal BD showed a higher risk 
of all cancers. (Gut Liver 2018;12:433-439)
Key Words: Intestinal Behçet’s disease; Neoplasms; Popula-
tion-based
INTRODUCTION
 Behçet’s disease (BD) is a chronic, multisystemic, immune-
mediated disorder that is characterized by recurrent oral and/
or genital ulcers, arthritis, and skin manifestations, as well 
as ocular, vascular, neurological, or intestinal involvement.1,2 
Immune-mediated diseases, which result from a dysregulated 
and hyperactive immune response, often cause chronic inflam-
mation,3,4 which can in turn, through inflammatory mediators, 
cause malignant cell transformation and carcinogenesis in sur-
rounding tissues.3,4 In addition, the immunomodulators used to 
treat immune-mediated diseases may affect cancer risk.5 Indeed, 
several studies have demonstrated that a variety of systemic, 
inflammatory, and rheumatic autoimmune diseases (particularly 
rheumatoid arthritis [RA], systemic lupus erythematosus [SLE], 
Sjogren’s syndrome, systemic sclerosis, and dermatomyositis), 
are associated with an increased risk of malignancy, especially 
lymphoma.6,7 In a few case series and case reports, BD has been 
sporadically associated with malignancy; however, the results 
of these investigations remain controversial.8-10 In particular, 
a number of studies have reported that BD is associated with 
hematologic diseases such as myelodysplastic syndrome (MDS) 
and aplastic anemia (AA), as well as with hematologic can-
cers.8,9,11,12 
Intestinal BD is diagnosed when there are typical ulcerative 
lesions in the gastrointestinal (GI) tract and clinical findings 
that meet the diagnostic criteria for BD.13,14 Given that Crohn’s 
disease (CD) and ulcerative colitis (UC) increase the risk of intes-
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tinal cancer, probably because they involve chronic inflamma-
tion of intestine,15-17 intestinal BD may also confer a high risk of 
colorectal cancer (CRC). However, until now, no data have been 
available regarding the risk of CRC in patients with intestinal 
BD. Thus, it is not known whether patients with intestinal BD 
require CRC surveillance in the same way as those with CD or 
UC do. 
Additionally, because intestinal BD, similarly to CD and 
UC, involves extraintestinal organs, it may increase the risk 
of extraintestinal cancers. However, the association between 
intestinal BD and extraintestinal cancer also remains unclear. 
Several studies have evaluated the relationship between BD and 
cancer.8-10 However, most of them were hospital-based chart 
reviews or case reports with inconsistent results, and none of 
them focused on intestinal BD. A number of Western popula-
tion-based studies have provided useful information regarding 
cancer risk in CD and UC. It follows that a population-based 
study into this matter in East Asia, where the prevalence of in-
testinal BD is higher than in the West, is also necessary. Such a 
population-based study will allow us to understand the associa-
tion between intestinal BD and cancer risk in a better way.
As the South Korean government operates a mandatory na-
tionwide insurance system (National Health Insurance [NHI]), 
all information regarding healthcare use is entered into a com-
prehensive database that is operated by the Health Insurance 
and Review Agency (HIRA). Thus, the HIRA database provides 
reliable information that allows us to study the national epide-
miology of intestinal BD. In the present study, we conducted a 
nationwide, population-based study using the HIRA database to 
determine the risk of all cancers, as well as that of site-specific 
cancers, in patients with intestinal BD.
MATERIALS AND METHODS
1. Data source 
This study used data that were provided by the NHI, which 
provides mandatory universal health insurance that covers all 
health services in South Korea, including admission, ambulatory 
care, and pharmaceutical services. Medical institutions submit 
information regarding healthcare use via an electronic form 
for reimbursement purposes; this information is integrated into 
the HIRA claims database, which covers the entire population 
of South Korea (51 million). The database contains information 
on all patients, including demographic characteristics; history 
of ambulatory care; principal diagnosis and comorbidities, as 
defined by the International Classification of Disease, 10th revi-
sion (ICD-10), prescriptions; and procedures. 
2. Patient identification 
In the present study, BD was diagnosed using the Interna-
tional Study Group diagnostic criteria for BD (recurrent oral 
ulceration plus two of the following criteria: recurrent genital 
ulceration, eye lesions, skin lesions, positive pathergy test).1 To 
ensure accurate diagnosis, intestinal BD was only determined 
in cases that met the following three criteria: appropriate di-
agnostic code (ICD-10: M35.2), performance of colonoscopy, 
prescription of 5-aminosalicylic acid (5-ASA) from a gastroen-
terology clinic for >1 month.18 Because 5-ASA is not used in 
the treatment of other organ involvement but only for intestinal 
involvement in BD, a prescription of 5-ASA can be regarded as 
confirmation of an intestinal BD diagnosis. It was for this rea-
son that prescription of 5-ASA was included in the definition of 
intestinal BD, and the start date of the 5-ASA prescription was 
regarded as the date of intestinal BD diagnosis. 
Beginning in 2006, the NHI initiated a registration program 
for 138 rare intractable diseases (RIDs), including BD, in order 
to subsidize the medical expenses of patients with RIDs. The 
diagnosis of BD must be made based on very strict diagnostic 
criteria (the International Study Group diagnostic criteria for 
BD) provided by the RID system and must be reviewed by the 
corresponding healthcare institution before being submitted 
to the NHI. Thus, data regarding RIDs are verified and reliable. 
However, intestinal BD cannot be identified separately in the 
RID program. In other words, only BD, but not intestinal BD, 
can be identified by the RID code (V139). Moreover, in South 
Korea, some patients may refuse to be registered in the RID 
program because job opportunities may be limited if they are 
registered in the RID program. Therefore, some patients with 
BD may have been missed through the RID program. For these 
reasons, we defined intestinal BD as cases that met the above 
three criteria rather than defining it with RID code. Instead, we 
investigated the proportion of patients with the RID code (V139) 
among patients who met the above three criteria. 
The source population for this study consisted of all patients 
with NHI claims data between 2010 and 2014. Because previous 
prevalent cases may have confounded incidence, we established 
a washout period of 1 year. Ultimately, we analyzed patients 
who had been diagnosed with intestinal BD between January 1, 
2011 and December 31, 2014.
3. Ascertainment of cancer incidence rates
To calculate the standardized incidence ratio (SIR) of cancer, 
we needed to determine the cancer incidence rate of the gen-
eral population. For achieving this, data were taken from the 
National Cancer Registry (NCR). The NCR is widely used as an 
official source of cancer data in South Korea. Indeed, one South 
Korean study reported that when patients admitted to hospitals 
because of cancer were regarded as incident cases, cancer inci-
dence rates were comparable between the NCR and insurance 
claims data.19 Based on this previous study, we defined incident 
cancer cases as those who had been admitted to hospital be-
cause of cancer (ICD-10: C00-C96).
Furthermore, we investigated the number of incident cases 
of MDS (ICD-10: D46) and AA (ICD-10: D61) because many 
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previous studies have reported that BD is associated with these 
diseases.8,9,11 We defined incident cases of MDS and AA as those 
who had been admitted to the hospital because of these diseases. 
4. Statistical analysis
To determine whether patients with intestinal BD had a 
higher risk of cancer incidence than the general population, we 
calculated the SIR (a ratio of observed to expected cancers) of 
all cancers and of site-specific cancers in these patients. The 
number of newly diagnosed cancer cases constituted the num-
ber of observed cancer cases. The expected number of cancer 
cases was calculated by multiplying the 2013 cancer incidence 
rate of the general population (as reported by the NCR and stan-
dardized for sex and age) with the person-years of patients with 
intestinal BD. The 95% confidence intervals (CIs) of the SIRs 
were calculated using the Poisson distribution.
5. Ethical considerations
All identifiable personal information in medical records was 
de-identified to comply with the privacy rule of the Health In-
surance Portability and Accountability Act. In addition, as the 
information in the HIRA database is encrypted, the database 
does not contain personal identifiers. This study protocol was 
approved by the Institutional Review Board of Severance Hospi-
tal, Yonsei University (IRB number: 4-2014-0796). 
RESULTS
1. Study population
In total, 365 patients with intestinal BD were newly diagnosed 
between 2011 and 2014. Of 365 patients, 308 (84.4%) met the 
RID code (V139). We excluded seven patients with an existing 
cancer, and 358 patients with intestinal BD were included in the 
present study; they were followed up until December 31, 2014 
(Fig. 1). 
The 358 patients with intestinal BD were followed for 715 
person-years (median follow-up time, 1.93 years; range, 0.003 
to 3.96 years). The demographic and clinical characteristics of 
the study population are presented in Table 1. The mean age at 
BD diagnosis was 43.9±14.4 years, and 46.7% of the patients 
were men.
2. Cancer risk in patients with intestinal BD
The SIRs of site-specific cancers in patients with intestinal BD 
are presented in Table 2. Among the 167 men with intestinal 
BD, four cases of cancer were observed (vs 1.92 expected); this 
did not constitute a significant difference in the risk of all can-
cers between men with intestinal BD and those in the general 
population (SIR, 2.08; 95% CI, 0.57 to 5.33). Regarding solid 
cancers in men, one developed stomach cancer (vs 0.36 expect-
ed: SIR, 2.82; 95% CI, 0.07 to 15.68) and one developed CRC 
(vs 0.29 expected: SIR, 3.48; 95% CI, 0.09 to 19.38). The risk of 
solid cancer was not significantly higher in men with intestinal 
BD than in the general population (SIR, 1.15; 95% CI, 0.14 to 
4.17). In contrast, men with intestinal BD did have a significant-
ly higher incidence of hematologic cancer (SIR, 23.90; 95% CI, 
2.89 to 86.32); two developed leukemia (vs 0.03 expected: SIR, 
79.18; 95% CI, 9.59 to 286.02). 
Among the 191 women with intestinal BD, eight cases of can-
cer were observed (vs 1.87 expected); thus, such women were at 
a higher risk of all cancers than those in the general population 
(SIR, 4.27; 95% CI, 1.84 to 8.41). Women with intestinal BD also 
had a higher risk of hematologic cancer (SIR, 34.47; 95% CI, 4.17 
Compare overall and site-specific cancer risk of 358
intestinal BD patients vs 51 million general population
7 Excluded because of previous cancer
: stomach cancer (n=1), colorectal cancer (n=1),
liver cancer (n=1), breast cancer (n=1),
thyroid cancer (n=1), multiple myeloma (n=1),
other cancer (n=1)
51 Million people in Korean NHI database
365 New intestinal BD patients identified between
2011 and 2014
358 Intestinal BD patients followed up until 2014
10 Intestinal BD patients developed cancer
Fig. 1. Flow chart of the study process.
NHI, National Health Insurance; BD, Behçet’s disease.
Table 1. Baseline Characteristics of the Study Population
Characteristic No. (%) Person-year
Total 358 715
Sex
    Men 167 (46.7) 348
    Women 191 (53.4) 367
Age at diagnosis, yr
    <40 129 (36.0) 268
    ≥40 229 (64.0) 447
Thiopurines ever use
    No 231 (64.5) 433
    Yes 127 (35.5) 282
Biologics ever use
    No 341 (95.3) 686
    Infliximab  9 (2.5)  15
    Adalimumab  8 (2.2)  14
Thiopurines and biologics ever use
    No 344 (96.1) 690
    Yes 14 (3.9)  25
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to 124.51); one developed non-Hodgkin lymphoma (NHL) (vs 
0.03 expected: SIR, 31.73; 95% CI, 0.80 to 176.79) and one de-
veloped leukemia (vs 0.02 expected: SIR, 56.24; 95% CI, 1.42 to 
313.32). Regarding solid cancers, there was one case of corpus 
uteri cancer (SIR, 21.67; 95% CI, 0.55 to 120.74), one of ovarian 
cancer (SIR, 24.70; 95% CI, 0.62 to 137.60), one of renal cancer 
(SIR, 48.34; 95% CI, 1.22 to 269.32), and one of thyroid cancer 
(SIR, 1.41; 95% CI, 0.04 to 7.87) among the women with intes-
tinal BD. The risk of renal cancer was significantly higher in 
women with intestinal BD than in the general population; how-
ever, the risk of all solid cancers was not significantly higher 
(SIR, 2.29; 95% CI, 0.63 to 5.87). 
The demographic and clinical data of patients who developed 
cancer during the study period are shown in Table 3. The mean 
age at cancer diagnosis was 51.5±11.9 years, and the median 
disease duration until the time of cancer diagnosis was 0.91 
years (range, 0.03 to 2.26 years). One patient (No. 10) developed 
both ovarian cancer and NHL; she was treated using thiopurines 
and biologics before her NHL diagnosis. Of the three patients 
who developed leukemia, two (Nos. 6 and 8) had been treated 
using thiopurines and biologics before their leukemia diagnosis. 
Because many studies have reported that BD is associated 
with MDS and AA,8,9,11 we further investigated the risk of these 
diseases in patients with BD in the present study. The result 
showed that one man and one woman developed MDS after 
their intestinal BD diagnosis; it followed that patients with 
Table 2. Risk of Site-Specific Cancer in Patients with Intestinal Behçet’s Disease
Cancer (ICD-10)
Men Women
Observed, n Expected, n SIR (95% CI) Observed, n Expected, n SIR (95% CI)
All cancer (C00–C96) 4 1.92 2.08 (0.57–5.33) 8 1.87 4.27 (1.84–8.41)
Solid cancer 2 1.73 1.15 (0.14–4.17) 4 1.74 2.29 (0.63–5.87)
    Stomach (C16) 1 0.36 2.82 (0.07–15.68) -
    Colon and rectum (C18–C20) 1 0.29 3.48 (0.09–19.38) -
    Corpus uteri (C54) - 1 0.05 21.67 (0.55–120.74)
    Ovary (C56) - 1 0.04 24.70 (0.62–137.60)
    Kidney (C64) - 1 0.02  48.34 (1.22–269.32)
    Thyroid (C73) - 1 0.71 1.41 (0.04–7.87)
Hematological cancer 2 0.08 23.90 (2.89–86.32) 2 0.06  34.47 (4.17–124.51)
    Non-Hodgkin lymphoma (C82–C85, C96) - 1 0.03 31.73 (0.80–176.79)
    Leukemia (C91–C95) 2 0.03 79.18 (9.59–286.02) 1 0.02  56.24 (1.42–313.32)
Other (remaining cancer codes) - 2* 0.07 27.44 (3.32–99.11)
ICD-10, International Classification of Diseases 10th revision; SIR, standardized incidence ratio; CI, confidence interval.
*C88.9 (malignant immunoproliferative disease, unspecified) and C78.6 (secondary malignant neoplasm of retroperitoneum and peritoneum).







Intestinal BD duration 
until cancer diagnosis, yr








1 M 69 Stomach 0.94 1.31 No No No
2 M 47 Sigmoid colon 0.03 2.08 No No No
3 F 39 Corpus uteri 0.90 2.04 No No No
4 F 27 Kidney 0.15 2.37 No No No
5 F 51 Thyroid 0.03 0.27 Yes No No
6 M 62 Leukemia 0.93 1.49 Yes Yes† No
7 M 58 Leukemia 1.19 1.24 Yes No No
8 F 51 Leukemia 0.81 3.00 Yes No Yes
9 F 56 Other (C88.9‡) 1.54 2.08 No No No
10 F 55 Ovary, non-Hodgkin lymphoma, 
and other (C78.6‡)
2.26 3.72 Yes Yes§ Yes
BD, Behçet’s disease; M, male; F, female.
*Age at the time of cancer diagnosis; †Azathioprine 25 mg for 2 months; ‡C88.9 (malignant immunoproliferative disease, unspecified) and C78.6 
(secondary malignant neoplasm of retroperitoneum and peritoneum); §Azathioprine 50 mg for 10 months.
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intestinal BD had a significantly higher risk of MDS than the 
general population (vs 0.008 expected: SIR, 118.62; 95% CI, 3.00 
to 660.88 in men and vs 0.005 expected: SIR, 218.98; 95% CI, 
5.54 to 1220.06 in women). Additionally, three of the women 
in the present study had developed MDS before their intestinal 
BD diagnosis. The SIR of AA in patients with intestinal BD were 
not calculated because the incidence rate of AA in the general 
population was not available; nonetheless, we identified four 
patients (two men and two women) who developed AA after 
their intestinal BD diagnosis.
DISCUSSION
In this first population-based analysis on cancer risk in intes-
tinal BD, we found that patients with intestinal BD (both men 
and women) had a higher risk of hematologic cancer, especially 
leukemia. Although men with intestinal BD were not at in-
creased risk of all cancers, women with intestinal BD were. 
Given that BD is an immune-mediated disease, it is interest-
ing, but not surprising, that patients with intestinal BD had a 
higher risk of hematological cancer in the present study. This 
result corroborates previous studies reporting higher risks of he-
matological cancers in patients with autoimmune diseases such 
as RA, SLE, and Sjogren’s syndrome.6,7 Additionally, several 
hospital-based studies have reported that BD is associated with 
hematological cancers, especially MDS.8,9,11 On the same note, 
two recent Taiwanese population-based studies showed that 
patients with BD had a higher risk of hematological malignancy 
(SIR, 4.2), especially NHL (SIR, 6.2 to 8.3).20,21 The present study 
also demonstrated that patients with intestinal BD had a higher 
risk of hematologic cancer and MDS than the general popula-
tion. Similarly, a South Korean hospital-based study indicated 
that intestinal ulceration was a characteristic finding in BD 
associated with bone marrow failure such as MDS and AA.12 
Although the pathogenesis of hematologic cancers in patients 
with intestinal BD is unclear, several mechanisms linking intes-
tinal BD and hematologic cancers have been posited. Firstly, BD 
may have affect bone marrow cells. Several inflammatory cy-
tokines, including tumor necrosis factor-α (TNF-α) interferon-γ, 
interleukin (IL)-6, and IL-8, play a role in the pathophysiology 
of both BD and hematologic cancers.22-25 High TNF-α expres-
sion has also been implicated in the increased reactive oxygen 
species (ROS) production that is observed in CD34+ bone mar-
row cells.24 Such frequent cytokine-mediated stimuli, as well as 
increased ROS production by neutrophils, may play a role in the 
development of hematologic cancers. Secondly, immune-me-
diated diseases and hematological cancers have similar genetic 
susceptibilities and environmental triggers (e.g., Epstein-Barr 
virus infection).26 These shared factors may be involved in the 
development of hematologic cancers in patients with intestinal 
BD. Indeed, one previous study reported that the cancer risk in 
patients with BD was highest within the first-year of follow-up, 
with 75% of hematological malignancies found within the first 
year.20 The authors also emphasized that hematological malig-
nancies appear earlier than non-hematological malignancies.20 
Our results also indicated that the risk of hematological cancer 
was higher in the early stage of the disease, because we could 
only investigate cancer risk at early stage of the disease (the 
median follow-up duration after intestinal BD diagnosis was 2 
years). The early occurrence of hematological cancers in patients 
with intestinal BD may be due to the pathophysiological mecha-
nisms that are shared by the diseases. Based on our results, we 
would suggest that hematological malignancies be screened for 
early after intestinal BD diagnosis. Thirdly, intestinal BD and 
hematologic cancers are linked in that immune dysregulation 
in intestinal BD may compromise immune surveillance against 
neoplasia and thus allow dysplastic cells to escape detection by 
the immune system. Fourthly, immunosuppressive drugs admin-
istered for intestinal BD may increase hematological malignancy 
risk. In fact, in the present study, thiopurines and/or biologics 
had been given to three out of four patients who developed he-
matological cancer. Finally, the disruption of the GI tract barrier 
caused by intestinal BD may expose patients to challenge from 
various microorganism antigens, leading to immune dysregula-
tion that contributes to the development of neoplasia. Some 
studies support this model.8,9 For instance, in a Chinese study, 
GI involvement was identified as an independent risk factor 
for malignancies, in patients with BD.8 Another South Korean 
study also demonstrated that intestinal involvement was more 
frequent in BD patients with malignancy than in those without.9 
In particular, patients with intestinal BD had a higher risk 
of leukemia; the concomitant occurrence of BD and leukemia 
has been found in a few case reports.27-29 Leukemia may be as-
sociated with BD because (1) tumor-associated antigens form 
immune complexes and cause vascular damage, (2) leukemic 
cells directly affect the vascular wall, or (3) antibodies directed 
against leukemic cells cross-react with endothelial cells and lead 
to direct vascular damage.30 
In contrast, the risk of solid cancers was not significantly 
higher in patients with intestinal BD than in the general popu-
lation, except for renal cancer in women. Both CD and UC 
increase the risk of intestinal cancer, probably because they in-
volve chronic intestinal inflammation.15-17 Therefore, we specu-
late that intestinal BD is associated with a higher risk of CRC 
as well, especially colon cancer that is confined to the ileocecal 
region, which is the most commonly involved region in cases of 
intestinal BD. In support of this claim, one previous case report 
showed colon cancer arising in an ileocecal ulcer scar that had 
been caused by intestinal BD.31 In addition, a Chinese study 
involving 41 BD patients who had developed malignancies re-
ported that CRC was the most common solid tumor associated 
with BD.8 However, contrary to our expectation, only one pa-
tient in the present study developed sigmoid colon cancer, and 
intestinal BD was not significantly associated with a higher risk 
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of colon cancer. Although CRC surveillance is recommended in 
patients with CD or UC,32 it may not be necessary in patients 
with intestinal BD. The short duration of follow-up in the pres-
ent study meant that we could only assess cancer risk in the 
early stages of BD; we could not analyze the long-term cancer 
risk. Therefore, it may be that we found an increased risk of he-
matologic cancer, but not solid cancer including colon cancer, 
because hematological cancer develops faster than solid cancer 
after it has been triggered. In future, extended, long-term stud-
ies are needed to clarify the causal relationship between intesti-
nal BD and colon cancer.
Meanwhile, the risk of renal cancer was higher in women 
with intestinal BD than those of the general population (SIR, 
48.3; 95% CI, 1.2 to 269.3). Even though only a single woman 
with BD developed renal cancer, the result reached statistical 
significance because the number of patients with intestinal BD 
was very small, and because renal cancer was very rare in the 
general population. Therefore, it may not be that women with 
intestinal BD really had a higher risk of renal cancer. In future, 
large-scale studies are required to identify solid cancers that are 
associated with intestinal BD. 
In the present study, the risk of all cancers was significantly 
increased in women with intestinal BD (SIR, 4.3; 95% CI, 1.8 
to 8.4), but not in men with intestinal BD (SIR, 2.1; 95% CI, 0.6 
to 5.3). This corroborates a Taiwanese population-based study 
showing that women with BD (SIR, 1.80; 95% CI, 1.14 to 2.7), 
but not men with BD (SIR, 1.08; 95% CI, 0.53 to 1.98), have 
a higher risk of all cancers.20 Moreover, a Chinese study also 
revealed that female gender was an independent risk factor for 
malignancy in patients with BD.8 Female gender may also be a 
risk factor for malignancy in patients with intestinal BD.
The present investigation was the first national, population-
based study regarding cancer risk in patients with intestinal BD. 
Nonetheless, it had several limitations. Firstly, even though we 
used the nationwide NHI database, our cohort of 358 patients 
with intestinal BD, which yielded 12 cases of cancer, was not 
large enough to analyze the risk of each site-specific cancer cor-
rectly. However, because intestinal BD is very rare, our study is 
meaningful. Secondly, we did not verify the diagnostic accuracy 
of intestinal BD. As we used insurance claims data, it is pos-
sible that some patients with intestinal BD had been missed, or 
that patients without intestinal BD had been misdiagnosed. To 
overcome this limitation, we only included cases of BD that had 
been diagnosed using the pertinent diagnostic code, wherein a 
colonoscopy had been performed, and wherein 5-ASA had been 
prescribed from a gastroenterology clinic for >1 month. More-
over, we confirmed that most patients (84.4%) met the RID code 
(V139). Therefore, we believe that the definition of intestinal BD 
diagnosis in the present study was reliable. Thirdly, the dura-
tion of follow-up was too short to assess the development of 
intestinal BD-associated cancers comprehensively. We were able 
to investigate cancer risk in the early stages of intestinal BD, 
but not long-term cancer risk. However, our study did not focus 
on cancer that occurred during treatment subsequent to a di-
agnosis of intestinal BD, but rather on the relationship between 
intestinal BD itself and cancer development. We speculate that 
patients with a predisposition toward developing intestinal BD 
have dysregulated immune responses even before the diagnosis 
of intestinal BD. This dysregulated immune response may affect 
cancer development even in the early stages of the disease. In 
addition, considering that dysregulated immune responses may 
occur after the onset of the first symptoms rather than after the 
objective diagnosis of intestinal BD or it may develop before the 
onset of the first symptoms as well, incident cancers diagnosed 
in the early stages of intestinal BD are likely to be related to in-
testinal BD itself. Fourthly, the risk of cancer was not stratified 
according to the use of thiopurines and/or biologics because the 
number of cases was too small. Therefore, there was a limitation 
in evaluating the effects of medication on cancer development. 
Fifthly, there might have been a detection bias through en-
hanced screening of cancer. Patients with intestinal BD are more 
likely to need health care and physician visits, as compared to 
the general population, and thus, they may have a higher rate 
of cancer detection than the general population. Finally, we did 
not investigate cancer risk in all patients with BD, focusing only 
on patients with intestinal BD. Future population-based studies 
must determine the type of cancers associated with BD, as well 
as whether the risk of various cancers differs between patients 
who have intestinal BD and those who have BD that does not 
involve the intestine.
In conclusion, both men and women with intestinal BD had a 
higher risk of hematologic cancer, especially leukemia. Women 
with intestinal BD also had a higher risk of all cancers. Further 
long-term studies are required to clarify the influence of intesti-
nal BD itself, and its medication, on cancer development. 
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